APOL6

APOL6 is a BH3-only proapoptotic member of the apolipoprotein L family that couples mitochondrial cell-death control to lipid-droplet metabolism (PMID:15671246, PMID:38167864). Its BH3 domain is required for mitochondria-mediated apoptosis: overexpression triggers cytochrome c and Smac/DIABLO release and caspase-9 activation, while a BH3-deletion allele is inert (PMID:15671246). APOL6 binds the anti-apoptotic protein Bcl-XL and promotes ROS-dependent, caspase-driven apoptosis; in parallel it blocks autophagy by inducing Beclin 1 degradation, p62 accumulation, and loss of LC3-II (PMID:21646352). Transient APOL6 expression is cytolytic by LDH release, though unlike other APOL family members recombinant APOL6 does not insert into planar lipid bilayers under acidic or positive-voltage conditions, distinguishing its membrane behavior from APOL1–APOL5 (PMID:34252458). In adipocytes APOL6 is a lipid-droplet-associated protein whose C-terminal domain directly binds the N-terminus of Perilipin1, preventing Plin1–HSL interaction and thereby inhibiting HSL-mediated lipolysis; APOL6, Plin1, and HSL form a trimeric complex on droplets, and APOL6 ablation reduces adipose mass and protects mice from diet-induced obesity while overexpression drives obesity and insulin resistance (PMID:38167864). APOL6 also links to ferroptosis: it interacts with ACSL4 within a STAT1/APOL6/GPX4 axis in bladder cancer (PMID:39187773), and in injured neurons CREB5-driven APOL6 suppresses lipid-droplet breakdown to limit fatty-acid oxidation, lipid peroxidation, and ferroptotic death (PMID:41700484). Expression is induced by IFNγ through PI3K/AKT signaling in macrophages (PMID:36208271) and tuned post-transcriptionally and at the chromatin level by additional regulators (PMID:31857580, PMID:34071504).

1. 2005 High

   Established APOL6 as a genuine proapoptotic effector and pinned its activity to a defined structural element, answering whether the protein actively drives cell death.

   Evidence Overexpression of wild-type vs. BH3-deletion APOL6 in p53-null DLD-1 and other cancer lines with cytochrome c/Smac release and caspase-9 activation readouts

   PMID:15671246

   Open questions at the time

   • No endogenous loss-of-function in physiological setting
   • Direct binding target of the BH3 domain not identified
   • Mechanism of caspase-8 activation unresolved
2. 2011 High

   Connected APOL6 to specific anti-apoptotic machinery and revealed a dual role suppressing autophagy, clarifying how it integrates two death/survival programs.

   Evidence Reciprocal overexpression/siRNA in lesion-derived cells; Co-IP for APOL6–Bcl-XL; ROS and caspase assays; LC3-II/p62/Beclin 1 Western and LC3 immunofluorescence

   PMID:21646352

   Open questions at the time

   • Mechanism of Beclin 1 degradation not defined
   • Whether Bcl-XL binding is BH3-mediated not tested
   • Cell-type generality unclear
3. 2015 Medium

   Tested whether APOL6 acts as an antiviral restriction factor, extending its functional repertoire beyond cell death.

   Evidence Transient overexpression in 293T cells with infectious HIV-1 production assay and replication-cycle follow-up

   PMID:25980612

   Open questions at the time

   • Single overexpression system
   • Exact replication step not pinpointed
   • No endogenous or knockdown validation
4. 2021 Medium

   Compared APOL6 membrane behavior against the rest of the family, showing its cytolytic activity is not explained by canonical bilayer insertion.

   Evidence Transient overexpression with LDH release and planar lipid bilayer electrophysiology of recombinant APOL1–APOL6 in parallel

   PMID:34252458

   Open questions at the time

   • Ion conductance properties uncharacterized
   • Mechanism of cytolysis without bilayer insertion unknown
   • Conditions tested may not capture native insertion
5. 2024 High

   Defined a non-apoptotic, metabolic role: APOL6 directly regulates lipolysis on lipid droplets and influences whole-body adiposity, reframing it as a metabolic regulator.

   Evidence Adipocyte knockdown/overexpression, Co-IP and domain-truncation mapping of APOL6–Plin1 and Plin1–HSL, KO and adipose-specific OE mice, lipolysis and LD/TAG assays

   PMID:38167864

   Open questions at the time

   • Structural basis of the trimeric complex not solved
   • Relationship between this LD function and apoptotic function unclear
   • Regulation of APOL6 LD targeting not defined
6. 2024 Medium

   Linked APOL6 to ferroptosis through a physical partner and a transcriptional upstream regulator, broadening its death-pathway involvement.

   Evidence Co-IP for APOL6–ACSL4, STAT1 modulation, and ferroptosis assays in bladder cancer cells

   PMID:39187773

   Open questions at the time

   • Single Co-IP without reciprocal validation
   • How APOL6 modulates GPX4 mechanistically unknown
   • STAT1–APOL6 regulation not directly demonstrated at the promoter
7. 2026 Medium

   Showed that CREB5-driven APOL6 suppresses lipid-droplet-fueled ferroptosis in neurons, unifying its LD and cell-death roles in a tissue context.

   Evidence scRNA/scATAC-seq, CREB5 KD/OE and APOL6 OE rescue in primary neurons and mouse SCI model with ROS, lipid peroxidation, free fatty acid, and axonal growth readouts

   PMID:41700484

   Open questions at the time

   • CREB5 transcriptional activation inferred from accessibility/rescue, not direct promoter binding
   • Single lab
   • Mechanism of LD-breakdown inhibition in neurons not at molecular resolution

• How APOL6's BH3/apoptotic activity, its lipid-droplet/lipolysis function, and its ferroptosis-modulating interactions are mechanistically reconciled within one protein remains unresolved.
• No structure of APOL6 or its complexes
• No unified model linking membrane/cytolytic, apoptotic, and metabolic functions
• Endogenous physiological function in non-adipose tissues largely untested